Laurus Labs Limited — Investor Meet, 05-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Laurus Labs delivered strong FY26 results, with revenues growing 23% YoY to INR 6,813 Cr and PAT surging 148% to INR 889 Cr. Q4 EBITDA margin stood at a healthy 28.9%. The CDMO business saw robust growth of 38% to INR 2,080 Cr, now contributing over 30% of total revenue. Affordable Medicines (Generics) also grew 18% to INR 4,733 Cr.

Management is confident in maintaining or improving EBITDA margins for FY27. The company plans a significant INR 3,000 Cr capex over the next two years, primarily for growth projects including new manufacturing units, commercial peptide capacity, and a fermentation greenfield. While ARV sales remain consistent in absolute terms, their percentage contribution will decline as CDMO expands. The outlook is positive, supported by a robust pipeline and diversified CDMO projects reducing concentration risk.